«JDRF
remains dedicated to accelerating the delivery of beta
cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct
islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
One hypothesis is that beta
cells in some
islets may
remain dormant until needed, and thus not age as quickly, Bonner - Weir says.